"I thought that it was a usual practice by all pharma is it not?."
yeah Slogger - i was under the impression this sort of approach was/is normal in the industry. Although clearly Lilly has pushed it a little too far (and got caught) in this instance.
Was thinking about this - for me this is a positive indicator for Axiron / ACR. yeah sure the fine is bad for Lilly - but it does show that Lilly is pushing Axiron marketing / sales wise very hard here. A good sign of support in my opinion!
Regards,
mita
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
-0.001(5.26%) |
Mkt cap ! $7.339M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $11.58K | 619.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 335415 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 516258 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |